Mary T Korytkowski1, Maria Brooks2, Manuel Lombardero2, Dilhari DeAlmeida3, Justin Kanter4, Vasudev Magaji5, Trevor Orchard2, Linda Siminerio6. 1. Division of Endocrinology, University of Pittsburgh, Pittsburgh, PA, USA mtk7@pitt.edu. 2. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Health Information Management, University of Pittsburgh, Pittsburgh, PA, USA. 4. UPMC, Pittsburgh, PA, USA. 5. Lehigh Valley Health Network, Diabetes and Endocrinology, Allentown, PA, USA. 6. Division of Endocrinology, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
BACKGROUND: Current treatment guidelines for type 2 diabetes (T2D) recommend individualized intensification of therapy for glycated hemoglobin (A1C) ≥ 7% in most patients. The purpose of this investigation was to explore the ability of an electronic medical record (EMR) to identify glycemic intensification strategies among T2D patients receiving pharmacologic therapy. METHODS: Patient records between 2005 and 2011 with documentation of A1C and active prescriptions for any diabetes medications were queried to identify potential candidates for intensification based on A1C ≥ 7% while on 1-2 oral diabetes medications (ODM). Patients with follow-up A1C values within 1 year of index A1C were grouped according to intensification with insulin, GLP-1 receptor agonists (GLP-1RA), a new class of ODM, or no intensification. Changes in A1C and continuation of intensification therapy were determined. RESULTS: A total of 4921 patients meeting inclusion criteria were intensified with insulin (n = 416), GLP-1RA (n = 68), ODM (n = 1408), or no additional therapy (n = 3029). Patients receiving insulin had higher baseline (9.3 ± 2.0 vs 8.3 ± 1.2 vs 8.3 ± 1.3 vs 7.6 ± 1.0%, P < .0001) and follow-up A1C (8.1 ± 1.6 vs 7.5 ± 1.2 vs 7.6 ± 1.3 vs 7.2 ± 1.1%, P < .0001) despite experiencing larger absolute A1C reductions (-1.2 ± 2.1 vs -0.8 ± 1.4 vs -0.7 ± 1.4 vs -0.3 ± 1.1%, P < .0001). Patients receiving GLP-1RA were more obese at baseline (BMI: 33.6 ± 7.1 vs 37.7 ± 6.1 vs 33.7 ± 6.8 vs 32.9 ± 7.1 kg/m(2), P < .0001) and follow-up (BMI: 33.9 ± 7.3 vs 36.6 ± 6.1 vs 33.8 ± 7.0 vs 32.4 ± 7.0 kg/m(2), P < .0001) despite experiencing more absolute weight reduction. Insulin was the most and GLP-1RA the least likely therapy to be continued. CONCLUSIONS: An EMR allows identification of prescribing practices and compliance with T2D treatment guidelines. Patients receiving intensification of glycemic medications had baseline A1C >8% suggesting that treatment recommendations are not being followed.
BACKGROUND: Current treatment guidelines for type 2 diabetes (T2D) recommend individualized intensification of therapy for glycated hemoglobin (A1C) ≥ 7% in most patients. The purpose of this investigation was to explore the ability of an electronic medical record (EMR) to identify glycemic intensification strategies among T2D patients receiving pharmacologic therapy. METHODS:Patient records between 2005 and 2011 with documentation of A1C and active prescriptions for any diabetes medications were queried to identify potential candidates for intensification based on A1C ≥ 7% while on 1-2 oral diabetes medications (ODM). Patients with follow-up A1C values within 1 year of index A1C were grouped according to intensification with insulin, GLP-1 receptor agonists (GLP-1RA), a new class of ODM, or no intensification. Changes in A1C and continuation of intensification therapy were determined. RESULTS: A total of 4921 patients meeting inclusion criteria were intensified with insulin (n = 416), GLP-1RA (n = 68), ODM (n = 1408), or no additional therapy (n = 3029). Patients receiving insulin had higher baseline (9.3 ± 2.0 vs 8.3 ± 1.2 vs 8.3 ± 1.3 vs 7.6 ± 1.0%, P < .0001) and follow-up A1C (8.1 ± 1.6 vs 7.5 ± 1.2 vs 7.6 ± 1.3 vs 7.2 ± 1.1%, P < .0001) despite experiencing larger absolute A1C reductions (-1.2 ± 2.1 vs -0.8 ± 1.4 vs -0.7 ± 1.4 vs -0.3 ± 1.1%, P < .0001). Patients receiving GLP-1RA were more obese at baseline (BMI: 33.6 ± 7.1 vs 37.7 ± 6.1 vs 33.7 ± 6.8 vs 32.9 ± 7.1 kg/m(2), P < .0001) and follow-up (BMI: 33.9 ± 7.3 vs 36.6 ± 6.1 vs 33.8 ± 7.0 vs 32.4 ± 7.0 kg/m(2), P < .0001) despite experiencing more absolute weight reduction. Insulin was the most and GLP-1RA the least likely therapy to be continued. CONCLUSIONS: An EMR allows identification of prescribing practices and compliance with T2D treatment guidelines. Patients receiving intensification of glycemic medications had baseline A1C >8% suggesting that treatment recommendations are not being followed.
Authors: Shih-Yin Chen; Kimberly Siu; Birgit Kovacs; Michael Stokes; Preethi Rao; Stephen Sander; Luke Boulanger Journal: Curr Med Res Opin Date: 2012-02-24 Impact factor: 2.580
Authors: Anders Ekedahl; Helen Brosius; Julia Jönsson; Hanna Karlsson; Maria Yngvesson Journal: Pharmacoepidemiol Drug Saf Date: 2011-08-22 Impact factor: 2.890
Authors: Qiaoyi Zhang; Srini Rajagopalan; Panagiotis Mavros; Samuel S Engel; Michael J Davies; Donald Yin; Larry Radican Journal: Adv Ther Date: 2010-05-10 Impact factor: 3.845
Authors: Faramarz Ismail-Beigi; Etie Moghissi; Margaret Tiktin; Irl B Hirsch; Silvio E Inzucchi; Saul Genuth Journal: Ann Intern Med Date: 2011-04-19 Impact factor: 25.391
Authors: Alexander Turchin; Michael E Matheny; Maria Shubina; James V Scanlon; Bonnie Greenwood; Merri L Pendergrass Journal: Diabetes Care Date: 2009-07 Impact factor: 19.112
Authors: Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews Journal: Diabetes Care Date: 2012-04-19 Impact factor: 19.112
Authors: John S Brownstein; Shawn N Murphy; Allison B Goldfine; Richard W Grant; Margarita Sordo; Vivian Gainer; Judith A Colecchi; Anil Dubey; David M Nathan; John P Glaser; Isaac S Kohane Journal: Diabetes Care Date: 2009-12-15 Impact factor: 19.112
Authors: Natalie Liu; Jen Birstler; Manasa Venkatesh; Lawrence P Hanrahan; Guanhua Chen; Luke M Funk Journal: Med Care Date: 2020-03 Impact factor: 3.178
Authors: Sam Miller; Tania Krumins; Haojin Zhou; Susan Huyck; Jeremy Johnson; Gregory Golm; Steven G Terra; James P Mancuso; Samuel S Engel; Brett Lauring Journal: Diabetes Ther Date: 2018-01-08 Impact factor: 2.945
Authors: Mary T Korytkowski; Esra Karslioglu French; Maria Brooks; Dilhari DeAlmeida; Justin Kanter; Manuel Lombardero; Vasudev Magaji; Trevor Orchard; Linda Siminerio Journal: BMJ Open Diabetes Res Care Date: 2016-05-26